SCHEMBL2391271

SCHEMBL2391271

COc1ccc(-c2ccc(C(=O)N3CCC(c4cccnc4)C3)cc2)cc1C(F)(F)F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.55
ROCK2 O75116 2/20 0.51
LMNA P02545 2/20 0.47
SPR P35270 1/20 0.47
PDE4B Q07343 1/20 0.47
SLC9A1 P19634 3/20 0.46
CYP2C9 P11712 1/20 0.46
APLNR P35414 1/20 0.45
ABL1 P00519 1/20 0.44
BCR P11274 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
ATM Q13315 1/20 0.44
HTT P42858 1/20 0.44
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
HIF1A Q16665 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2389841 0.83 NAMPT (0.54) NAMPTROCK2LMNASPRSLC9A1
SCHEMBL2389787 0.83 NAMPT (0.61) NAMPTSPRSLC9A1CYP2C9NPC1
SCHEMBL2390969 0.83 NAMPT (0.59) NAMPTSPRSLC9A1CYP2C9ABL1
SCHEMBL2390000 0.82 NAMPT (0.61) NAMPTROCK2SPRSLC9A1CYP2C9
SCHEMBL2391631 0.82 NAMPT (0.58) NAMPTROCK2LMNASPRPDE4B
SCHEMBL2390747 0.82 ROCK2 (0.62) NAMPTROCK2LMNASPRAPLNR
SCHEMBL14670316 0.81 NAMPT (0.52) NAMPTLMNASPRSLC9A1CYP2C9
SCHEMBL2389382 0.81 NAMPT (0.57) NAMPTROCK2LMNASPRPDE4B
SCHEMBL2391295 0.81 NAMPT (0.58) NAMPTLMNASPRNPC1RAB9A
SCHEMBL2392931 0.81 NAMPT (0.56) NAMPTROCK2LMNASPRAPLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367679-B2 Biaryl carboxamides MERCK SHARP & DOHME CORP. (US) 2013-02-05 US claimed
US-20110230498-A1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME CORP. 2011-09-22 US claimed
EP-2375904-B1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME (US) 2014-05-28 EP disclosed
US-8367679-B2 Biaryl carboxamides MERCK SHARP & DOHME CORP. (US) 2013-02-05 US disclosed
EP-2375904-A1 BIARYL CARBOXAMIDES Merck Sharp & Dohme Corp. (US) 2011-10-19 EP disclosed
US-20110230498-A1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME CORP. 2011-09-22 US disclosed
WO-2010077624-A1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME CORP. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230498-A1 BIARYL CARBOXAMIDES PAFAH1B3, PAFAH1B2, FAAH2 NAMPT 2170/4885ROCK2 1766/4885LMNA 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.